Acasti Pharma (ACST) Coverage Initiated by Analysts at Benchmark
Analysts at Benchmark started coverage on shares of Acasti Pharma (NASDAQ:ACST) in a report released on Friday. The firm set a “buy” rating and a $7.00 price target on the biopharmaceutical company’s stock.
Separately, ValuEngine raised Acasti Pharma from a “sell” rating to a “hold” rating in a research report on Monday, November 20th.
Shares of Acasti Pharma (NASDAQ ACST) opened at $1.01 on Friday. Acasti Pharma has a 12-month low of $0.84 and a 12-month high of $3.36. The stock has a market capitalization of $15.06, a price-to-earnings ratio of -1.28 and a beta of 1.49.
Acasti Pharma Company Profile
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.